Plus Therapeutics

Showing 1 posts of 1 posts found.

Plus Therapeutics initiates part B of phase 1/2a ReSPECT-LM trial for leptomeningeal metastase

September 6, 2023
Research and Development Oncology, Plus Therapeutics, clinical trial, leptomeningeal metastase

Plus Therapeutics has announced that the first patient has begun treatment in part B of the ReSPECT-LM phase 1/2a dose …

Latest content